Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology | Yervoy